Pharmacokinetics in children
The following kinetic parameters have been observed in children aged 2-12 years after an oral dose of 2.5 mg:
Cl: 315.9 ml/hour/kg
Vd: 2.58 l/kg
T½: 5.1 hours
Tmax: 0.95-2 hours
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Muscle spasms |
- Oral
-
3 months
up to
8 years
-
8 years
up to
18 years
|
| Spierspasmen van cerebrale of spinale oorsprong |
- Intrathecal
-
≥ 4 years
Initial dose: test dose 25-50 mcg/day intrathecally; depending on the response, increase by 25 mcg every 24 hours to a maximum of 100 mcg. Maintenance dose: Effect of the test dose < 12 hours: double the effective test dose, administer over 24 hours. Effect of the test dose > 12 hours: effective test dose, over 24 hours. After the first 24 hours, slowly adjust the dose daily in steps of max. 5-15% of the daily dose. Max. 1000 mcg/day
|
Renal impaiment in children > 3 months
When used orally:
- GFR ≥ 50 ml/min/1.73 m2: dose adjustment is not necessary.
- GFR 30-50 ml/min/1.73 m2: 100% of normal reversal dose, interval between 2 doses: 24 hours, then dose according to effect and side effect.
- GFR 10-30 ml/min/1.73 m2: 100% of normal reversal dose, interval between 2 doses: 24 hours, then dose according to effect and side effect.
- GFR <10 ml/min/1.73 m2: general advice is not given.
When used intrathecally: dose adjustment is not necessary.
Clinical consequences
With impaired renal function, the renal clearance of baclofen decreases. This increases the risk of adverse reactions.
Clinical Effects:
Characteristic symptoms of overdose include central nervous system depression, respiratory depression, convulsions, myoclonia, muscle weakness, and hypotonia and hyporeflexia.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Sedation (particularly at the start of treatment), vomiting and diarrhoea.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Reduce the dose in muscular hypotonia. Down titrate the dosage when stopping after long-term therapy.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
References
-
Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
-
Novartis Pharma BV, SPC Lioresal (RVG 06347), www.cbg-meb.nl, Geraadpleegd 26 mei 2010, http://db.cbg-meb.nl/IB-teksten/h06347.pdf
-
Sintetica GmHb, SmPC Baclofen (RVG 120889) 06-09-2018, www.geneesmiddelinformatiebank.nl
-
NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021
Therapeutic Drug Monitoring
Overdose